HS
PALI icon

HighVista Strategies’s Palisade Bio PALI Stock Holding History

HighVista Strategies’s Portfolio PALI Stock Details PALI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.53M Buy
2,019,326
+719,295
+55% +$1.31M 0.98% 29
2025
Q4 		$3.06M Buy
+1,300,031
New +$2.5M 0.79% 39

Other funds holding PALI

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

HighVista Strategies's PALI Position: Q1 2026 in Review

HighVista Strategies increased its Palisade Bio (PALI) stake by 55% in Q1 2026, buying an estimated $1.31M and bringing the position to 2,019,326 shares worth $3.53M. The position accounts for 0.98% of the portfolio, ranked #29.

HighVista Strategies first reported a position in PALI in Q4 2025 and has held it in 2 quarters since. 96 funds tracked by Wall St. Rank hold PALI as of Q1 2026.

  • HighVista Strategies held 2,019,326 shares of Palisade Bio worth $3.53M as of Q1 2026.
  • HighVista Strategies bought 719,295 Palisade Bio shares in Q1 2026, an estimated $1.31M.
  • Palisade Bio made up 0.98% of HighVista Strategies's portfolio in Q1 2026, its #29 holding.
  • HighVista Strategies first reported a position in Palisade Bio in Q4 2025 and has held it in 2 quarters since.
  • 96 funds tracked by Wall St. Rank held Palisade Bio as of Q1 2026.

Based on HighVista Strategies's 13F filing for Q1 2026, filed 15 May 2026.